The company entered into underwriting agreements on February 11, 2025 with the underwriters, and said it will offer $600 million of 4.700% notes due 2027, $550 million of 5.050% notes due 2030 and $600 million of 5.500% notes due 2035.

1. 01

   The company entered into underwriting agreements on February 11, 2025 with the underwriters, and said it will offer $600 million of 4.700% notes due 2027, $550 million of 5.050% notes due 2030 and $600 million of 5.500% notes due 2035.

2. 02

   Zimmer Biomet said the notes will bear interest at 4.700% for the notes due 2027, 5.050% for the notes due 2030 and 5.500% for the notes due 2035, payable semi-annually in arrears on February 19 and August 19, with the first interest payment on August 19, 2025. The notes mature in 2027, 2030 and February 19, 2035, respectively.

3. 03

   The company said the sale of the notes is scheduled to close on February 19, 2025, subject to customary closing conditions. Some underwriters or their affiliates hold 3.550% of the notes due 2025 and will receive their proportionate share of net proceeds if those proceeds are used to redeem or repay those notes.

4. 04

   The company said Goldman Sachs & Co. LLC served as its exclusive financial advisor in connection with the merger agreement for Paragon 28, Inc., and will receive customary fees, expense reimbursement and indemnification for that role.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.